About Grail
Industry:
Diagnostics
Founded:
2016
Founders:
Illumina spin-off
Status:
Subsidiary of Illumina
Funding & Growth
Total Raised:
$2B+
Valuation:
Part of Illumina
Stage:
Acquired
Key Investors:
Illumina
ARCH Venture
Jeff Bezos
✓ Pros
- • Mission-driven (early cancer detection)
- • Galleri test success
- • Strong data science
- • Bay Area location
- • Well-funded
✗ Cons
- • Regulatory challenges
- • Illumina integration uncertainty
- • Competitive landscape
- • Legal/antitrust issues